Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) within the prescribed time-period. Concurrent with preparing the Form 10-K, the Registrant was negotiating a commercial agreement subject to a binding exclusivity period that ended March 28, 2025. Disclosure related to the distribution agreement would include a Subsequent Events note to the Registrant’s financial statements and potentially elsewhere in the Form 10-K. Management devoted considerable time and effort to the negotiations, which impacted the Registrant’s ability to complete the Form 10-K by the March 31, 2025 due date without unreasonable effort or expense. The distribution agreement was signed on March 31, 2025 and will be described in the Form 10-K. The Registrant intends to file the Form 10-K on April 1, 2025. The Registrant expects to continue to report substantial doubt exists about its ability to continue as a going concern. Forward-Looking Statements This Form 12b-25 contains forward-looking statements, which are based on management’s current expectations or beliefs about the Registrant’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant’s intention to file the Form 10-K and on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25

Nuo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) within the prescribed time-period because the Registrant is awaiting final review of its financial statements by its independent registered public accounting firm. The Registrant expects to continue to report substantial doubt exists about its ability to continue as a going concern. The Registrant currently intends to file the Form 10-K within the 15-calendar day extension provided by Rule 12b-25. Forward-Looking Statements This Form 12b-25 contains forward-looking statements, which are based on management’s current expectations or beliefs about the Registrant’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant’s intention to file the Form 10-K and on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25

Nuo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2023 (the “Form 10-Q”) within the prescribed time-period because the Registrant needs additional time to compile and analyze supporting documentation to permit final review of its financial statements by its independent registered public accounting firm. The Registrant currently intends to file the Form 10-Q within the 5-calendar day extension provided by Rule 12b-25. Forward-Looking Statements This Form 12b-25 contains forward-looking statements, which are based on management’s current expectations or beliefs about the Registrant’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant’s intention to file the Form 10-Q and on or before the fifth calendar day following the prescribed due date for filing the Form 10-Q. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25

Nuo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”) within the prescribed time-period because the Registrant is awaiting final review of its financial statements by its independent registered public accounting firm. In contrast to the Registrant’s preceding comprehensive annual report covering three fiscal years of 2019, 2020, and 2021, the Form 10-K will cover two fiscal years including 2022 when the Registrant reestablished commercial operations. As a result, additional effort and expense has been required to complete the 2022 year-end reporting processes and related audit procedures. The Registrant expects to continue to report substantial doubt exists about its ability to continue as a going concern. The Registrant currently intends to file the Form 10-K within the 15-calendar day extension provided by Rule 12b-25. Forward-Looking Statements This Form 12b-25 contains forward-looking statements, which are based on management’s current expectations or beliefs about the Registrant’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant’s intention to file the Form 10-K and on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25

Nuo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its comprehensive Annual Report on Form 10-K for the fiscal year ended 2021 (“Form 10-K”) within the prescribed time period because the Registrant is awaiting final review of its financial statements by our independent registered public accounting firm and completion of the XBRL conversion of its financial statements. The Form 10-K will cover the fiscal years ended December 31, 2019, 2020 and 2021. The Registrant currently intends to file the comprehensive Form 10-K on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Forward-Looking Statements This Form 12b-25 contains forward-looking statements, which are based on management’s current expectations or beliefs about the Registrant’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant’s intention to file the Form 10-K and on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25